NASDAQ:ADAP - Adaptimmune Therapeutics Price Target & Analyst Ratings Sign in or create an account to add this stock to your watchlist. Get Started $3.84 -0.04 (-1.03 %) (As of 03/19/2019 10:39 AM ET)Previous Close$3.88Today's Range$3.8250 - $3.9152-Week Range$3.60 - $14.63Volume28,140 shsAverage Volume284,194 shsMarket Capitalization$362.57 millionP/E Ratio-4.00Dividend YieldN/ABeta1.31 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Analyst Ratings Adaptimmune Therapeutics (NASDAQ:ADAP) Price Target and Consensus Rating (How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.5 Wall Street analysts have issued ratings and price targets for Adaptimmune Therapeutics in the last 12 months. Their average twelve-month price target is $16.00, suggesting that the stock has a possible upside of 316.67%. The high price target for ADAP is $20.00 and the low price target for ADAP is $12.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."Today30 Days Ago90 Days Ago180 Days AgoConsensus Rating: BuyBuyBuyBuyConsensus Rating Score: 3.003.003.003.00Ratings Breakdown: 0 Sell Rating(s)0 Hold Rating(s)5 Buy Rating(s)0 Strong Buy Rating(s)0 Sell Rating(s)0 Hold Rating(s)5 Buy Rating(s)0 Strong Buy Rating(s)0 Sell Rating(s)0 Hold Rating(s)5 Buy Rating(s)0 Strong Buy Rating(s)0 Sell Rating(s)0 Hold Rating(s)5 Buy Rating(s)0 Strong Buy Rating(s)Consensus Price Target: $16.00$16.00$16.00$19.3333Price Target Upside: 316.67% upside204.76% upside204.76% upside80.52% upsideAdaptimmune Therapeutics (NASDAQ:ADAP) Consensus Price Target History Adaptimmune Therapeutics (NASDAQ:ADAP) Analyst Ratings History Show: Only the Most Recent Rating From Each Brokerage All Ratings For This Stock DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails12/13/2018SunTrust BanksLower Price TargetBuy$12.00Medium11/6/2018CowenReiterated RatingBuyMedium10/22/2018Raymond JamesLower Price TargetOutperform ➝ Buy$20.00 ➝ $16.00High9/17/2018GuggenheimInitiated CoverageBuyHigh6/4/2018Leerink SwannBoost Price TargetOutperform$20.00High(Data available from 3/19/2017 forward) This page was last updated on 3/19/2019 by MarketBeat.com StaffFeatured Article: Why is the ROA ratio important?